(Press-News.org) Administration of a bolus dose of the anticoagulant drug abciximab into the coronary artery involved in causing a certain type of heart attack among patients who were undergoing a percutaneous coronary intervention and also receiving another anticoagulant resulted in reduction in the size of damage to the heart muscle at 30 days, while a procedure that involved use of a catheter to remove the blood clot blocking that coronary artery did not produce these results, according to a study appearing in JAMA. The study is being published early online to coincide with its presentation at the American College of Cardiology's annual scientific sessions.
"Primary percutaneous coronary intervention [PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries] is widely accepted as the most effective reperfusion [restoration of blood flow] modality for ST-segment elevation myocardial infarction [STEMI; a certain pattern on an electrocardiogram following a heart attack]. However, myocardial recovery after primary PCI is often suboptimal despite restoration of coronary blood flow, in part due to thrombus embolization [small blood clots blocking the arteries] resulting in impaired microvascular perfusion [blood flow]," according to background information in the article. Two strategies proposed to reduce this complication after PCI include bolus (large dose) infusion of intracoronary abciximab and manual thrombus aspiration (use of a catheter for removal of a clot). "However, conflicting results have been reported as to whether intracoronary abciximab and manual aspiration thrombectomy reduce infarct [heart muscle damage] size or improve clinical outcomes, in part because of differences in patient selection, devices, and study methodology."
Gregg W. Stone, M.D., of Columbia University Medical Center and New York–Presbyterian Hospital, New York, and colleague investigated whether bolus intracoronary abciximab, manual aspiration thrombectomy, or both would reduce infarct size in high-risk patients with STEMI. The study, conducted between November 2009 and December 2011, included 452 patients presenting at 37 sites in 6 countries within 4 hours of STEMI due to blockage in a certain area of the heart (proximal or mid left anterior descending artery occlusion) undergoing primary PCI with the anticoagulant bivalirudin. The patients were randomized to bolus intracoronary abciximab delivered locally (via a drug delivery catheter) at the infarct lesion site vs. no abciximab and to manual aspiration thrombectomy vs. no thrombectomy. Infarct size was assessed at 30 days by cardiac magnetic resonance imaging (cMRI).
Evaluable cMRI results at 30 days were present in 181 and 172 patients randomized to intracoronary abciximab vs. no abciximab, respectively, and in 174 and 179 patients randomized to manual aspiration vs. no aspiration, respectively. The researchers found that patients randomized to intracoronary abciximab compared with no abciximab had a significant decrease in infarct size measured as a percentage of total myocardial mass (median [midpoint], 15.1 percent vs. 17.9 percent) and absolute infarct mass (median, 18.7 g vs. 24.0 g), but not in abnormal wall motion (the movement of the wall of the heart during contraction) score. Patients randomized to aspiration thrombectomy vs. no aspiration had no significant difference in infarct size (median, 17.0 percent vs. median, 17.3 percent), absolute infarct mass (median, 20.3 g vs. 21.0 g), or abnormal wall motion score.
"The principal findings from this multicenter, prospective, randomized trial in patients presenting early in the course of a large evolving anterior STEMI undergoing primary PCI with bivalirudin anticoagulation are as follows: (1) bolus intracoronary abciximab delivered to the infarct lesion site significantly but modestly reduced the primary end point of infarct size at 30 days; (2) in contrast, manual aspiration thrombectomy did not significantly reduce infarct size; and (3) indices of myocardial reperfusion, ST-segment resolution, and 30-day clinical event rates were not significantly different between the randomized groups," the authors conclude.
###(JAMA. 2012;307(17):doi:10.1001/jama.2012.421. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: This study was sponsored and funded by Atrium Medical. Atrium supplied the local drug delivery catheter. Aspiration catheters were provided at a discount by Medtronic. Bivalirudin was provided at no charge by The Medicines Company. All other study devices and drugs were commercially purchased. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.
Infusion of drug into the coronary artery may help reduce size of heart damage after heart attack
2012-03-26
ELSE PRESS RELEASES FROM THIS DATE:
The long, err, short of it
2012-03-26
BOSTON, MA—No one really wants the short end of the stick, in this case the short end of a chromosome. Telomeres, which are DNA-protein complexes at the ends of chromosomes, can be thought of as protein "caps" that protect chromosomes from deteriorating and fusing with neighboring chromosomes.
It is typical for telomeres to shorten as cells divide and chromosomes replicate over time. Now a new study from Brigham and Women's Hospital (BWH) suggest a strong link between telomere shortening and poor cardiovascular outcomes in patients with acute coronary syndrome.
The ...
Researchers discover first-ever link between tiny genetic structures, imminent heart attack risk
2012-03-26
SALT LAKE CITY — Researchers at the Intermountain Medical Center Heart Institute have, for the first time ever, made a connection between tiny genetic molecules called microRNAs and the imminent threat of a heart attack, according to a new study.
The findings are an important first step toward developing a method for predicting heart attacks in people who show no outward signs, but may be at great risk of having a heart attack. The research group will present study results today (March 25) at the American College of Cardiology's 61st Annual Scientific Session in Chicago.
"About ...
Diabetes associated with higher risk of cardiovascular problems in men
2012-03-26
BOSTON, MA—According to a new study by researchers at Brigham and Women's Hospital (BWH), men with type 2 diabetes treated with insulin without a history of cardiovascular disease (CVD) were at higher risk for major cardiovascular events (e.g., death, heart attack, stroke) compared with men who had a history of CVD.
The study is being presented at the American College of Cardiology 2012 Annual Scientific Session, March 24 to 26 in Chicago.
Using data from the global REACH Registry, researchers evaluated the magnitude of risk of diabetes mellitus on cardiovascular ...
Large-scale, community-wide preventive initiative dramatically impacts CV risk profile
2012-03-26
CHICAGO -- A population-wide community and clinical prevention program involving 10,000 adults meaningfully reduced the cardiovascular (CV) risk profile among a substantial portion of the population as indicated by those participating in screenings. Findings also indicate the level of improvements differ by gender for specific cardiovascular risk factors. The results will be presented March 25 at the 61st annual American College of Cardiology (ACC) scientific session.
Hearts Beat Back: The Heart of New Ulm Project (HONU) is a demonstration project aimed at reducing heart ...
Some 90-year-old heart attack patients have 'excellent' outcomes with coronary stenting
2012-03-26
CHICAGO—Selected patients 90 years and older who experience an acute heart attack, or ST-elevation myocardial infarction (STEMI), have reasonable outcomes with coronary stenting, and should be considered for reperfusion therapy, based on a scientific poster being presented at the 61st annual American College of Cardiology (ACC) scientific session.
Current STEMI guidelines do not specifically address age-related reperfusion decisions, even number though the number of people over 90 years old in the U.S. is expected to quadruple by 2050.
"Cardiologists are a little ...
New Dallas Marriott City Center Introduces Centric
2012-03-26
As the Dallas Arts District continues to grow and reshape northern downtown Dallas, the new Dallas Marriott City Center introduces Centric, the latest addition to the restaurant scene - a hotspot within walking distance of the AT&T Performing Arts Center, the Meyerson Symphony Center, the Dallas Museum of Art and more.
Located at 650 N. Pearl St. at the Plaza of the Americas, the upscale restaurant features a Texas eclectic menu by Executive Chef Yoni Heredia, with fresh ingredients sourced from local producers including Dallas' Mozzarella Company, Jimmy's Food Store ...
Significant mismatch between PCI capable-hospitals and need
2012-03-26
CHICAGO—There is an imbalance between the rapid growth of cardiac catheterization laboratories, which provide percutaneous coronary intervention (PCI) procedures, relative to the growth in the overall U.S. population, as well as patients who experience an acute heart attack, or ST-elevation myocardial infarction (STEMI), according to a study presented March 25 at the 61st annual American College of Cardiology (ACC) scientific session.
PCI is the preferred treatment strategy for patients who undergo STEMI. However, distance and access to PCI remains a determining factor ...
'Coaching Boys into Men' an effective tool for stopping teen dating violence
2012-03-26
Male high school athletes' ability to recognize and intervene to stop dating violence -- the physical, sexual and emotional aggression prevalent in adolescent romantic relationships -- is improved with the intervention of some of the most important role models in young men's lives: their coaches.
A new study conducted in Sacramento, Calif., led by UC Davis researchers has found that a structured program delivered by coaches, called "Coaching Boys into Men," is effective for discouraging adolescent dating violence. The research is published online today in the Journal ...
Protein found to regulate spread of pancreatic cancer cells
2012-03-26
Researchers at Queen Mary, University of London have identified a new protein that makes pancreatic cancer cells less 'sticky' and therefore less able to attach to and invade other tissue.
The protein, known as S100PBP, does this by suppressing a second protein called cathepsin Z. The research team has shown that cathepsin Z makes pancreatic cancer cells sticky, allowing them to spread to their surrounding environment. Prior to this study nothing was known about the function of S100PBP in the body or the role that cathepsin Z plays in pancreactic cancer.
The findings, ...
Few young women with cancer take steps to preserve fertility during treatments
2012-03-26
A new study has found that very few young women with cancer take steps to preserve their fertility while undergoing cancer therapy. Also, certain groups of young women are more likely to do so than others. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that efforts are needed to provide counseling on fertility preservation in reproductive-aged women diagnosed with cancer.
More than 120,000 women under 50 years of age are diagnosed with cancer each year in the United States. As cancer survival rates are improving, ...